Login to Your Account



With Phase III Trials Planned, Telik Aims To Sell 5M Shares

By Randall Osborne


Friday, September 13, 2002
On the heels of an encouraging meeting with the FDA regarding Phase III trials of the company's drug for ovarian cancer and non-small-cell lung cancer, Telik Inc. said it plans to pull down cash through an offering of about 5 million shares under a shelf registration filed in June. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription